Vicki L Keedy
Overview
Explore the profile of Vicki L Keedy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
894
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Haddox C, Hornick J, Roland C, Baldini E, Keedy V, Riedel R
Cancer Treat Rev
. 2024 Oct;
131:102846.
PMID: 39454547
Dedifferentiated liposarcoma (DDLPS) is a malignant mesenchymal neoplasm in desperate need of novel therapeutic approaches. Often occurring in conjunction with well-differentiated liposarcoma (WDLPS), DDLPS can behave more aggressively and exhibits...
2.
DAngelo S, Araujo D, Abdul Razak A, Agulnik M, Attia S, Blay J, et al.
Lancet
. 2024 Mar;
403(10435):1460-1471.
PMID: 38554725
Background: Afamitresgene autoleucel (afami-cel) showed acceptable safety and promising efficacy in a phase 1 trial (NCT03132922). The aim of this study was to further evaluate the efficacy of afami-cel for...
3.
Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas
Kummar S, Shen L, Hong D, McDermott R, Keedy V, Casanova M, et al.
Cancer
. 2023 Sep;
129(23):3772-3782.
PMID: 37769113
Background: Larotrectinib, a first-in-class, highly selective tropomyosin receptor kinase (TRK) inhibitor, has demonstrated efficacy in adult and pediatric patients with various solid tumors harboring NTRK gene fusions. This subset analysis...
4.
Bui N, Dietz H, Farag S, Hirbe A, Wagner M, Van Tine B, et al.
Cancers (Basel)
. 2023 May;
15(9).
PMID: 37174084
Background: Dedifferentiated chondrosarcoma (DDCS) is a rare subset of chondrosarcoma. It is an aggressive neoplasm characterized by a high rate of recurrent and metastatic disease with overall poor outcomes. Systemic...
5.
Thompson J, Koch R, Keedy V, Magge D
World J Surg Oncol
. 2023 Jan;
21(1):24.
PMID: 36710330
Synovial sarcoma is a rare soft tissue sarcoma which frequently involves the upper or lower extremities. Soft tissue sarcomas including synovial sarcoma have a propensity to metastasize to the lungs,...
6.
Walker J, Bradley 3rd J, Luckenbaugh A, Lambright E, Sandvall B, Keedy V, et al.
Am Surg
. 2022 May;
88(9):2230-2232.
PMID: 35503030
Radiation-associated sarcomas (RASs) are rare entities that tend to have an aggressive course and poor prognosis. Criteria for diagnosis of radiation-associated sarcoma include therapeutic radiation preceding the development of sarcoma,...
7.
Dharmani C, Wang E, Salas M, McCabe C, Diggs A, Choi Y, et al.
Future Oncol
. 2022 Feb;
18(13):1595-1607.
PMID: 35105158
For drugs with enhanced serious safety risks, Risk Evaluation and Mitigation Strategy (REMS) may be required. Pexidartinib is approved for treatment of adult symptomatic tenosynovial giant cell tumor (TGCT) associated...
8.
Peterfy C, Chen Y, Countryman P, Chmielowski B, Anthony S, Healey J, et al.
Future Oncol
. 2022 Jan;
18(12):1449-1459.
PMID: 35040698
Monitoring treatment of tenosynovial giant cell tumor (TGCT) is complicated by the irregular shape and asymmetrical growth of the tumor. We compared responses to pexidartinib by Response Evaluation Criteria in...
9.
Eder J, Doroshow D, Do K, Keedy V, Sklar J, Glazer P, et al.
JCO Precis Oncol
. 2022 Jan;
5:466-472.
PMID: 34994649
Purpose: Tumors with neomorphic mutations in IDH1/2 have defective homologous recombination repair, resulting in sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition. The Olaparib Combination trial is a phase II, open-label...
10.
Cousin S, Blay J, Garcia I, de Bono J, Le Tourneau C, Moreno V, et al.
Int J Cancer
. 2021 Nov;
150(6):993-1006.
PMID: 34724226
Molibresib is an orally bioavailable, selective, small molecule BET protein inhibitor. Results from a first time in human study in solid tumors resulted in the selection of a 75 mg...